Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Treatments and evolution of depressive disorders are highly heterogeneous, with difficult-to-treat depression (DTD) presenting elevated medical and economic burdens, particularly when accompanied with suicidality. This study analyzed clinical profiles, evolution, and costs associated with major depressive disorder (MDD), MDD with suicide risk (MDD-SR), DTD, and DTD with suicide risk (DTD-SR) over 12 months, considering initial healthcare pathways. Methods: A cohort of 3,941 individuals aged ≥18 years was recruited between 2014 and 2018 in four Madrid hospitals. Patients were classified according to their first contact with mental health services through emergency settings (emergency-first) or outpatient settings (outpatient-first). Sociodemographic data, International Classification of Diseases (ICD-10) diagnoses, and healthcare resource use were extracted from electronic health records and the MeMind digital ecosystem. Suicide risk was assessed using the Mini International Neuropsychiatric Interview (MINI)-based suicide risk assessment, and clinical profiles and costs were compared. Results: Compared with outpatient-first patients, emergency-first patients showed greater depression severity, psychiatric comorbidities, and suicide risk (p < 0.001), along with increased rates of DTD (p = 0.021), poorer treatment outcomes, and higher global costs. Patients with DTD or suicide risk displayed greater depression severity, lower treatment response, more frequent relapses, psychiatric hospitalization, and antidepressant augmentation strategies compared to MDD-only patients. Emergency-first DTD-SR patients incurred the highest costs (€15,358.1 [SD = 16,415.1]/patient/year). Suicide risk was strongly associated with probable relapses and DTD. Conclusions: Despite the high economic burden, important needs remain unmet for DTD, especially for patients showing suicide risk with a first contact through the emergency setting. Earlier detection, innovative treatments, improved access to healthcare, and integration in mobile health programs should mitigate these gaps and improve clinical outcomes in this vulnerable population.
Source: Frontiers in Psychiatry
Authors: Sergio Benavente, Alba Parra, Jorge Lopez-Castroman, Ismael Conejero, Pablo Alonso-Torres, Tatiana Caraballo López, Pablo Carrasco Arteaga, Enrique Baca-García
Institutions: Comunidad de Madrid, Centre National de la Recherche Scientifique, Inserm, Université de Montpellier, Universidade de Santiago de Compostela, Centro de Investigación Biomédica en Red de Salud Mental, Centre Hospitalier Universitaire de Nîmes, Institut de Génomique Fonctionnelle, Neuropsychiatrie : Recherche Epidemiologique et Clinique, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Johnson & Johnson (United States), Catholic University of the Maule, Hospital Universitario Rey Juan Carlos, Hospital Universitario General de Villalba
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W4417166880
